GlassScriptPhysician profile
Swati Pullamaraju
NPI 1982915633
$2,916.04
in general payments reported to CMS, 2019-2025
26 companies · $607 in 2025
The $607 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $192 · 2021: $216 · 2022: $585 · 2023: $581 · 2024: $606 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,734 · Education: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,733.66 |
| Education | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $626.38 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astellas Pharma US INC | $437.93 | 2023-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $320.66 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $194.13 | 2020-2025 | Evenity, Prolia, Prolia |
| Novartis Pharmaceuticals Corporation | $169.31 | 2022-2024 | |
| Inspire Medical Systems, INC. | $147.55 | 2022-2024 | Inspire |
| Amarin Pharma, INC. | $128.30 | 2019-2021 | |
| Abbvie INC. | $110.32 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $101.02 | 2022-2025 | Farxiga, Breztri |
| Abbott Laboratories | $82.32 | 2025 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $81.11 | 2022 | |
| Pfizer INC. | $76.49 | 2020-2024 | |
| Exact Sciences Corporation | $61.57 | 2023-2024 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $57.45 | 2019-2023 | Aptima |
| Merck Sharp & Dohme LLC | $54.67 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $47.96 | 2021 | |
| Glaxosmithkline, LLC. | $41.28 | 2021-2023 | Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $32.98 | 2022-2025 | |
| Edwards Lifesciences Corporation | $24.14 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Corcept Therapeutics | $23.05 | 2025 | Korlym |
| Noven Therapeutics, LLC | $21.78 | 2025 | Xelstrym |
| Sumitomo Pharma America, INC. | $17.62 | 2025 | Gemtesa |
| Ge Healthcare | $17.29 | 2019 | |
| Supernus Pharmaceuticals, INC. | $16.35 | 2023 | Qelbree |
| Qiagen, LLC | $12.82 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swati Pullamaraju listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.